<unk>  is used in two forms. A capsule form (Cometriq) is used since 2012, to treat medullary thyroid cancer and a tablet form (Cabometyx) is used since 2016, as a second line treatment for renal cell carcinoma. In the United States,<unk>  (Cabometyx) is also indicated for the treatment of people aged twelve years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are ineligible or refractory to radioactive iodine.
Cabozantinib
Avapritinib
Encorafenib
Sorafenib
Entrectinib
Enasidenib
Dabrafenib
Abrocitinib